SGLT2抑制剂恩格列净对喂食西方饮食的ApoE-/-小鼠动脉粥样硬化的有益作用
研究在喂食西方饮食20周的48只雄性ApoE-/-小鼠中比较恩格列净与格列美脲对动脉粥样硬化的影响。恩格列净组动脉粥样硬化斑块面积显著小于对照组或格列美脲组,炎症和胰岛素抵抗改善似为其机制。
要点
- 恩格列净组主动脉弓/瓣膜区斑块面积显著小于对照组或格列美脲组。
- 恩格列净降低胰岛素抵抗及循环TNF-α、IL-6、MCP-1、血清淀粉样蛋白A和尿微量白蛋白。
- 恩格列净减轻体重和脂肪量、肝脏脂滴、脂肪细胞大小及斑块和脂肪组织炎症细胞浸润。
核心结论
- 炎症和胰岛素抵抗的改善似乎是恩格列净减轻动脉粥样硬化的机制。
研究设计与样本
- 48只5周龄雄性ApoE-/-小鼠喂食西方饮食20周,分为对照组(生理盐水,154 mmol/l NaCl)、格列美脲0.1 mg/kg组、恩格列净1 mg/kg组和恩格列净3 mg/kg组(每组n=12)。
- 评估主动脉弓/瓣膜区斑块大小和组成及血液和组织心血管风险变量,用HOMA和脂联素水平估计胰岛素抵抗,用双能X线吸收法测定体成分。
主要发现
- 治疗8周后,恩格列净和格列美脲组血糖水平下降。
- 恩格列净组主动脉弓/瓣膜区动脉粥样硬化斑块面积显著小于对照组或格列美脲组。
- 恩格列净治疗后胰岛素抵抗及循环TNF-α、IL-6、单核细胞趋化蛋白-1(MCP-1)、血清淀粉样蛋白A和尿微量白蛋白浓度下降,且与斑块大小显著相关。
- 与对照组或格列美脲组相比,恩格列净降低体重和脂肪量、肝脏脂滴、脂肪细胞大小、Tnf、Il6和Mcp-1(又称Ccl2)mRNA表达及斑块和脂肪组织炎症细胞浸润。
- 恩格列净治疗升高脂联素水平。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: A recent large clinical study has shown that empagliflozin has a lower rate of cardiovascular and all-cause mortality when compared with placebo in patients with type 2 diabetes. We investigated the effect of empagliflozin (compared with glimepiride) on the progression of atherosclerosis, and its possible mechanisms of action. METHODS: Forty-eight 5-week-old male ApoE -/- mice were fed a western diet for 20 weeks and divided into four groups: control (saline, 154 mmol/l NaCl), glimepiride 0.1 mg/kg, empagliflozin 1 mg/kg and empagliflozin 3 mg/kg (n = 12/group). Plaque size and composition in the aortic arch/valve areas and cardiovascular risk variables in the blood and tissues were evaluated. Insulin resistance was estimated by HOMA and adiponectin levels. Body composition was determined using dual-energy x-ray absorptiometry. RESULTS: After 8 weeks of treatment, the empagliflozin and glimepiride groups exhibited decreased blood glucose levels. Atherosclerotic plaque areas in the aortic arch/valve were significantly smaller in the empagliflozin groups than in the control or glimepiride groups. Insulin resistance and circulating concentrations of TNF-α, IL-6, monocyte chemoattractant protein-1 (MCP-1), serum amyloid A and urinary microalbumin decreased after empagliflozin treatment, and this significantly correlated with plaque size. Empagliflozin treatment reduced weight and fat mass, lipid droplets in the liver, fat cell size, mRNA expression of Tnf, Il6 and Mcp-1 (also known as Ccl2) and the infiltration of inflammatory cells in plaque and adipose tissue compared with the control or glimepiride group. Empagliflozin treatment increased adiponectin levels. CONCLUSIONS/INTERPRETATION: Improvements in inflammation and insulin resistance seem to be mechanisms involved in the mitigation of atherosclerosis by empagliflozin.
引用
- Han JH, Oh TJ, Lee G, et al. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE -/- mice fed a western diet. Diabetologia. 2016. PMID: 27866224. doi:10.1007/s00125-016-4158-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。